Category: Disclosures

[Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement for Human Hyaluronidase Core Technology (ALT-B4) / 2025-03-17

March 17, 2025August 5, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen signed an exclusive license agreement with a subsidiary of AstraZeneca for its human hyaluronidase technology (ALT-B4), featuring an upfront payment of KRW 36.37B (US$ 25M) and milestone payments of up to KRW 1.05T (US$ 725M), bringing the total potential contract value up to KRW 1.09T…

Disclosures, Bio & Healthcare

[Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement for Human Hyaluronidase Core Technology (ALT-B4) / 2025-03-17

March 17, 2025August 5, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen signed an exclusive license agreement with a subsidiary of AstraZeneca for its human hyaluronidase technology (ALT-B4), featuring an upfront payment of KRW 29.10B (US$ 20M) and milestone payments of up to KRW 843.78B (US$ 580M), bringing the total potential contract value up to KRW 872.88B…

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Systems (272210) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-03-17

March 17, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems has resolved to participate in a third-party capital increase of affiliated company HAA No.1 PTY LTD, acquiring 220.2 million shares for approximately KRW 202.67B (AUD 220.2M). Following the acquisition, its ownership stake will be 60.0%. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…

Disclosures, Defense

[Disclosure] SK Hynix (000660 / SKHY) – Decision on Business Acquisition (Correction) / 2025-03-17

March 17, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DARTMarket: KOSPI (000660) 💡 3-Second Summary SK Hynix has revised the expected acquisition base date (closing date) for the second and final closing of its Intel NAND business acquisition from March 15, 2025, to March 31, 2025, reflecting current transaction progress. 📊 Key Disclosure Contents & Financial Figures 📝 Editor’s…

Semiconductors, Disclosures

[Disclosure] Celltrion (068270) – Submission of Audit Report / 2025-03-17

March 17, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received and submitted its Audit Report for FY2024 (34th fiscal term) from Samil PwC, obtaining an ‘Unqualified’ audit opinion for both consolidated and separate financial statements. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Final Approval of Financial Statements…

Disclosures, Bio & Healthcare

[Disclosure] Jeju Semiconductor (080220) – (Correction) Change in Sales or Profit/Loss Structure by 30% (15% for Large Corporations) or More / 2025-03-14

March 14, 2025August 3, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Jeju Semiconductor has filed a corrected disclosure reflecting audit adjustments, revising its 2024 consolidated operating profit to KRW 9.58B and net profit to KRW 19.41B. 📊 [Key Disclosure Contents & Summary of Major Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Audit Adjustments and Preliminary Figures…

Semiconductors, Disclosures

[Disclosure] ALTEOGEN (196170) – Resolution on Convocation of General Shareholders Meeting / 2025-03-14

March 14, 2025August 5, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen decided to convene its Annual General Meeting of Shareholders on March 31, 2025, to vote on key agenda items including the approval of financial statements, re-election of CEO Soon Jae Park, new appointment of Vice President Sang Lak Choi as Inside Director, appointment of Auditor,…

Disclosures, Bio & Healthcare

[Disclosure] Samsung Biologics (207940) – Results of Annual General Meeting of Shareholders / 2025-03-14

March 14, 2025August 7, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that all agenda items presented at its 14th Annual General Meeting (AGM) of Shareholders—including approval of financial statements, amendments to the articles of incorporation, appointments of directors and audit committee members, and approval of director remuneration limits—were approved as originally proposed. 📊…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Share Retirement Decision / 2025-03-14

March 14, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided through a board resolution to retire 1,101,379 treasury common shares (book value of approximately KRW 184.3B) to stabilize its stock price and enhance shareholder value, with the retirement scheduled for March 25, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key…

Disclosures, Bio & Healthcare

[Disclosure] Hanmi Semiconductor (042700) – Submission of Audit Report / 2025-03-13

March 13, 2025August 1, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The company received ‘Unqualified’ audit opinions from Samil PricewaterhouseCoopers for both consolidated and separate financial statements for FY2024. Annual consolidated revenue reached KRW 558.9B and operating profit stood at KRW 255.4B. 📊 [Key Disclosure Contents & Summary of Major Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Semiconductors, Disclosures